title: Strategies of mucosal immunotherapy for allergic diseases.
abstract: Incidences of allergic disease have recently increased worldwide. Allergen-specific immunotherapy (SIT) has long been a controversial treatment for allergic diseases. Although beneficial effects on clinically relevant outcomes have been demonstrated in clinical trials by subcutaneous immunotherapy (SCIT), there remains a risk of severe and sometimes fatal anaphylaxis. Mucosal immunotherapy is one advantageous choice because of its non-injection routes of administration and lower side-effect profile. This study reviews recent progress in mucosal immunotherapy for allergic diseases. Administration routes, antigen quality and quantity, and adjuvants used are major considerations in this field. Also, direct uses of unique probiotics, or specific cytokines, have been discussed. Furthermore, some researchers have reported new therapeutic ideas that combine two or more strategies. The most important strategy for development of mucosal therapies for allergic diseases is the improvement of antigen formulation, which includes continuous searching for efficient adjuvants, collecting more information about dominant T-cell epitopes of allergens, and having the proper combination of each. In clinics, when compared to other mucosal routes, sublingual immunotherapy (SLIT) is a preferred choice for therapeutic administration, although local and systemic side effects have been reported. Additionally, not every allergen has the same beneficial effect. Further studies are needed to determine the benefits of mucosal immunotherapy for different allergic diseases after comparison of the different administration routes in children and adults. Data collected from large, well-designed, double-blind, placebo-controlled, and randomized trials, with post-treatment follow-up, can provide robust substantiation of current evidence.
authors.affiliation: Department of Biotechnology, National Formosa University, Yunlin, Taiwan.
authors.forename: Yi-Ling
authors.initials: YL
authors.lastname: Ye
authors.forename: Ya-Hui
authors.initials: YH
authors.lastname: Chuang
authors.forename: Bor-Luen
authors.initials: BL
authors.lastname: Chiang
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000485:Allergens / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D000818:Animals; D000941:Antigens / Q000276:immunology; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002648:Child; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology; D003888:Desensitization, Immunologic / Q000379:methods*; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D018928:Immunity, Mucosal; D051379:Mice; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control
chemical_list: D000276:Adjuvants, Immunologic; D000485:Allergens; D000941:Antigens; D016207:Cytokines; D018984:Epitopes, T-Lymphocyte